TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 3, 2015, Pages 2690-2699

  Xu, Yongcan ^a   Rao, Qiu ^a   Xia, Qiuyuan ^a   Shi, Shanshan ^a   Shi, Qunli ^a   Ma, Henghui ^a   Lu, Zhenfeng ^a   Chen, Hui ^a   Zhou, Xiaojun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Diagnostic marker; Renal cell carcinomas; TFE3 translocation renal cell carcinomas; TMED6 COG8 chimera

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; COG8 PROTEIN, HUMAN; TFE3 PROTEIN, HUMAN; TMED6 PROTEIN, MOUSE; TUMOR MARKER; VESICULAR TRANSPORT ADAPTOR PROTEIN; VESICULAR TRANSPORT PROTEIN;

ADOLESCENT; ADULT; AGED; CHROMOSOME 11; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE FUSION; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X CHROMOSOME; YOUNG ADULT;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADOLESCENT; ADULT; AGED; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, X; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC; VESICULAR TRANSPORT PROTEINS; YOUNG ADULT;

EID: 84933033768     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Chow WH, Dong LM and Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-257.
3. Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
4. Pflueger D, Sboner A, Storz M, Roth J, Comperat E, Bruder E, Rubin MA, Schraml P and Moch H. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia 2013; 15: 1231-1240.
5. Ross H and Argani P. Xp11 translocation renal cell carcinoma. Pathology 2010; 42: 369-373.
6. Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinie V and Escudier B. Targeted agents in metastatic Xp11 translocation/ TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010; 21: 1834-1838.
7. Folpe AL and Deyrup AT. Alveolar soft-part sarcoma: a review and update. J Clin Pathol 2006; 59: 1127-1132.
8. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M and Fletcher CD. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013; 52: 775-784.
9. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR and Weiss SW. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 2010; 34: 1395-1406.
10. Malouf GG, Monzon FA, Couturier J, Molinie V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG and Tannir NM. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 2013; 19: 4673-4684.
11. Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P and Aulmann S. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 2012; 25: 308-315.
12. Kim SH, Choi Y, Jeong HY, Lee K, Chae JY and Moon KC. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch 2011; 459: 299-306.
13. Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA and Hirsch MS. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol 2011; 20: 129-137.
14. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, Lonigro RJ, Schroth G, Kumar-Sinha C and Chinnaiyan AM. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009; 106: 12353-12358.
15. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N and Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
16. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
17. Mahon FX and Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res 2014; 20: 310-322.
18. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
19. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ and Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
20. Guo Y, Ma J, Lyu X, Liu H, Wei B, Zhao J, Fu S, Ding L and Zhang J. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. BMC Cancer 2014; 14: 834.
21. Argani P and Ladanyi M. The evolving story of renal translocation carcinomas. Am J Clin Pathol 2006; 126: 332-334.
22. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE and Ladanyi M. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005; 29: 230-240.
23. Argani P and Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005; 25: 363-378.
24. Wu A, Kunju LP, Cheng L and Shah RB. Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation- associated and unusual clear cell subtypes. Histopathology 2008; 53: 533-544.
25. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, Billis A, Hicks J, De Marzo AM, Reuter VE and Ladanyi M. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007; 31: 1149-1160.
26. Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, Waldert M, Marberger M, Susani M and Haitel A. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol 2012; 137: 761-768.
27. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA and Ladanyi M. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159: 179-192.
28. Argani P, Antonescu CR, Couturier J, Fournet JC, Sciot R, Debiec-Rychter M, Hutchinson B, Reuter VE, Boccon-Gibod L, Timmons C, Hafez N and Ladanyi M. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol 2002; 26: 1553-1566.
29. Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J and Cooper CS. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997; 15: 2233-2239.
30. Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC and Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 2003; 22: 5374-5378.
31. Wang X, Yang R, Jadhao SB, Yu D, Hu H, Glynn-Cunningham N, Sztalryd C, Silver KD and Gong DW. Transmembrane emp24 protein transport domain 6 is selectively expressed in pancreatic islets and implicated in insulin secretion and diabetes. Pancreas 2012; 41: 10-14.
32. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT and Vieillefond A. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 2008; 32: 656-670.
33. Smith RD and Lupashin VV. Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation. Carbohydr Res 2008; 343: 2024-2031.